Viper venom for diabetic nephropathy

Slides:

Advertisements

Similar presentations

Management of IgA nephropathy: Evidence-based recommendations

Advertisements

Diagram representing the renin–angiotensin–aldosterone system

Native ace enzyme Angiotensin-converting enzyme (EC ), or "ACE" indirectly increases blood pressure by causing blood vessels to constrict. It does.

Volume 84, Issue 2, Pages (August 2013)

Combination therapy with ACE inhibitors and angiotensin II receptor blockers in chronic renal disease: New therapeutic world beyond blood pressure reduction

Volume 82, Issue 1, Pages 7-8 (July 2012)

Frederic Rahbari-Oskoui, MD, MS American Journal of Kidney Diseases

Francesco Locatelli, Lucia Del Vecchio, Simeone Andrulli, Sara Colzani

Membranous nephropathy: When and how to treat

Viper venom for diabetic nephropathy

Correction to Lancet Diabetes Endocrinol 2015; 3: 263–74

Status of chronic kidney disease prevention programs: International Federation of Kidney Foundation Members 2005/2007 Joanna M. Smith, Susan A. Mott,

Volume 80, Issue 10, Pages (November 2011)

Drugs Acting on the Renin-Angiotensin-Aldosterone System

‘Progressive diabetic nephropathy. How useful is microalbuminuria

Renoprotective effects of vitamin D analogs

Propofol as a panacea for acute kidney injury?

Volume 81, Issue 7, Pages (April 2012)

Audit-based education: a potentially effective program for improving guideline achievement in CKD patients Moniek C.M. de Goeij, Joris I. Rotmans Kidney.

Volume 80, Issue 9, Pages (November 2011)

Resistant Hypertension and the Pivotal Role for Mineralocorticoid Receptor Antagonists: A Clinical Update 2016 Murray Epstein, MD, Daniel A. Duprez,

Volume 71, Issue 8, Pages (April 2007)

Correction to Lancet Diabetes Endocrinol 2015; 3: 263–74

Volume 84, Issue 1, Pages (July 2013)

Comorbidity and confounding in end-stage renal disease

Steven J. Rosansky, Richard J. Glassock Kidney International

Volume 74, Issue 3, Pages (August 2008)

Cardiac Production of Angiotensin II and Its Pharmacologic Inhibition: Effects on the Coronary Circulation Axel Schmermund, M.D., Lilach O. Lerman, M.D.,

Volume 72, Issue 12, Pages (December 2007)

Renal risk scores: Progress and prospects

Volume 86, Issue 2, Pages (August 2014)

Fernando Elijovich, Cheryl L. Laffer Kidney International

Achieving blood pressure targets during dialysis improves control but increases intradialytic hypotension A. Davenport, C. Cox, R. Thuraisingham Kidney.

Volume 86, Issue 5, Pages (November 2014)

Cardiac medications and their association with cardiovascular events in incident dialysis patients: Cause or effect? Areef Ishani, Charles A. Herzog,

David M. Charytan, John P. Forman Kidney International

Special deLIVERy: podocyte injury promotes renal angiotensin II generation from liver- derived angiotensinogen David I. Ortiz-Melo, Robert F. Spurney

Can we prevent donor-specific antibodies from developing after ABO-incompatible kidney transplantation? Lionel Rostaing, Nassim Kamar Kidney International

Volume 53, Issue 4, Pages (April 1998)

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

The future of renoprotection: Frustration and promises

Volume 73, Issue 10, Pages (May 2008)

Nephrology Crossword: Peritoneal Dialysis

Volume 84, Issue 5, Pages (November 2013)

Nephrology Crossword: Glomerulonephritis

Comparative Superiority of ACE Inhibitors Over Angiotensin Receptor Blockers for People With CKD: Does It Matter? Dimitris Mavridis, PhD American Journal.

Volume 57, Issue 2, Pages (October 2000)

Volume 82, Issue 9, Pages (November 2012)

Volume 81, Issue 7, Pages (April 2012)

Carmine Zoccali, Francesca Mallamaci Kidney International

Volume 73, Issue 5, Pages (March 2008)

Volume 63, Issue 4, Pages (April 2003)

Renin–angiotensin system blockade and diabetes: moving the adipose organ from the periphery to the center Oliver Lenz, Alessia Fornoni Kidney International

Volume 83, Issue 4, Pages (April 2013)

Volume 81, Issue 12, Pages (June 2012)

Volume 64, Issue 4, Pages (October 2003)

Volume 61, Issue 2, Pages (February 2002)

Volume 74, Issue 9, Pages (November 2008)

Kathryn J. Wiggins, Darren J. Kelly Kidney International

Innovative teaching tools in nephrology

Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: Pathophysiology and indications

The international realities of live donor kidney transplantation

Friends, social networks, and progressive chronic kidney disease

Volume 57, Issue 2, Pages (October 2000)

Volume 75, Issue 8, Pages (April 2009)

Combination angiotensin-converting enzyme inhibitor (ACEI)/angiotensin II receptor blocker (ARB) reduced risk for renal end point versus ACEI or ARB. Effect.

Schematic of the interaction between the renin-angiotensin-aldosterone system (RAAS) system and the natriuretic peptides and how the RAAS modulators and.

Proteinuria and hypertension with tyrosine kinase inhibitors

Renin-angiotensin-aldosterone-system inhibition is safe in the preoperative period surrounding carotid endarterectomy Andrea M. Steely, MD, Peter W.

Presentation transcript:

Viper venom for diabetic nephropathy M. Luiza Caramori Kidney International Volume 81, Issue 7, Pages 615-616 (April 2012) DOI: 10.1038/ki.2011.460 Copyright © 2012 International Society of Nephrology Terms and Conditions

Figure 1 Renin–angiotensin–aldosterone system. The renin–angiotensin–aldosterone system can be interrupted at different steps. Renin inhibitors inhibit the conversion of angiotensinogen into angiotensin I. Inhibitors of angiotensin-converting enzyme (ACE inhibitors) reduce the formation of the more potent angiotensin II, while angiotensin II receptor antagonists, also known as angiotensin receptor blockers (ARBs) or AT1-receptor antagonists, can prevent angiotensin II from acting on angiotensin receptors (AT). ACE cleaves a number of other peptides, including bradykinin, and this function is also inhibited by ACE inhibitors. Kidney International 2012 81, 615-616DOI: (10.1038/ki.2011.460) Copyright © 2012 International Society of Nephrology Terms and Conditions